The technology for manufacturing complex medicines like cell and gene therapy hasn’t kept pace with the wave of scientific discoveries fueling them. Because many approaches to treating rare and life-threatening diseases are so new, the process of making them hasn’t progressed beyond methods only meant for small batch, often originating in academic labs. As clinical proof of concept is recognized, advanced to later stage development becomes more challenging and introduces regulatory implications often slowing the pace of approval of these life-saving therapies.

In this panel discussion, we will take a deeper look into what has hindered growth and scalability of these exciting therapies, and how disruptive technology and cross-industry partnerships are driving change in this young and exciting field of medicine.

• Best practices for successful partnerships between industries, clients, service providers, technology partners, and academics
• Viral vector technology platforms
• Cell therapy technology platforms
• Investment and risk-sharing concepts in the development of novel therapeutics
• Product life cycle management

Moderator: 

David DiGiusto, Ph.D., Chief Technology Officer, Resilience

Panellists:

John Kerwin, Ph.D. – Technical Head of Gene Therapy Franchise, Resilience

Bruce Thompson, Ph.D., Technical Head of Cell Therapy, Resilience

Boro Dropulic, Ph.D., Executive Director, Caring Cross

Jason Foster, Chief Executive Officer and Executive Director, Ori Biotech

Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania; President, International Society for Cell & Gene Therapy